88353-04-2

Usage

Uses

Used in Industrial Material Production:
Dodecanedioic acid, mono(phenylmethyl) ester is used as a key ingredient in the production of polymers, resins, and adhesives for its ability to improve the flexibility and durability of these materials.
Used in Manufacturing of Coatings and Sealants:
Dodecanedioic acid, mono(phenylmethyl) ester is used as a component in coatings and sealants to enhance their performance characteristics, such as adhesion, flexibility, and resistance to environmental factors.
Used in Pharmaceutical and Personal Care Industries:
Dodecanedioic acid, mono(phenylmethyl) ester is used as a lubricant and emollient in pharmaceutical and personal care products due to its beneficial properties for skin and hair care applications.
It is crucial to handle Dodecanedioic acid, mono(phenylmethyl) ester with care and follow proper safety measures to mitigate potential health and environmental risks associated with its use and disposal.

Upstream product

• 4834-98-4 1,12-dodecanedioyl dichloride 
• 100-51-6 benzyl alcohol 
• 693-23-2 1,12-dodecanedioic acid 
• 100-39-0 benzyl bromide 
• 111-20-6 1,10-decanedioic acid 
• 104-57-4 benzyl formate 
• 100-44-7 benzyl chloride 

Downstream Products

• 213614-61-0 1,2-bis[11-(benzyloxycarbonyl)undecanoyl]-sn-glycero-3-phosphocholine 
• 1026086-58-7 C₅₇H₇₈O₉Si 
• 158069-69-3 C₁₉H₂₇ClO₃ 
• 1400998-37-9 C₃₉H₄₄N₂O₄ 

Relevant academic research and scientific papers

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

BIVALENT TARGETED CONJUGATES

The invention provides conjugates that comprise a bivalent targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates, compositions comprising the bidentate targeting ligands and the conjugates, as well as methods for targeting therapeutic nucleic acids with the bidentate conjugates. The conjugates are useful to target therapeutic nucleic acids.

THERAPEUTIC METHODS

The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.

PROTAC-mediated degradation of class i histone deacetylase enzymes in corepressor complexes

We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3. The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand. Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degradation strategy as an alternative to class I HDAC inhibition.

TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

Improved Syntheses of Benzyl Hydraphile Synthetic Cation-Conducting Channels

The tris(macrocycle)s that function in bilayer membranes as ion channels have recently shown versatile new applications such as antibiotic synergists and as agents for direct injection chemotherapy. This report records the development of new and versatile approaches to these molecules that produce significantly better overall yields for a group of previously reported hydraphiles having spacer chains ranging from octylene to hexadecylene.

BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Bolaamphiphilic compounds are provided according to formula (I): where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering HIV active drugs into animal or human brain.

Synthesis of fluorescent carboxylic acid ligands for construction of monolayers on nanostructures

Two new long-chain carboxylic acids (1, 2) bearing strong fluorescent group pyrene as ligands for Self-Assembled Monolayers (SAMs) have been synthesized. The multistep targeted synthesis is accomplished by use of Pyren-1-yl methylamine hydrochloride and employing simplified synthetic protocols. Compound 2 contains a chiral center purposely introduced along the atom chain in order to make it suitable for chiro-optical studies of the resulting SAMs.

Synthesis, characterization, and in vitro transfection activity of charge-reversal amphiphiles for DNA delivery

A series of charge-reversal lipids were synthesized that possess varying chain lengths and end functionalities. These lipids were designed to bind and then release DNA based on a change in electrostatic interaction with DNA. Specifically, a cleavable ester linkage is located at the ends of the hydrocarbon chains. The DNA release from the amphiphile was tuned by altering the length and position of the ester linkage in the hydrophobic chains of the lipids through the preparation of five new amphiphiles. The amphiphiles and corresponding lipoplexes were characterized by DSC, TEM, and X-ray, as well as evaluated for DNA binding and DNA transfection. For one specific charge-reversal lipid, stable lipoplexes of approximately 550 nm were formed, and with this amphiphile, effective in vitro DNA transfection activities was observed.

Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof

One aspect of the present invention relates to a synthetic non-viral vector composition for gene therapy. Another aspect of the invention relates to the use of the composition for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention also encompasses a pharmaceutical composition (useful for delivery of nucleic acids to a cell), containing a non-cationic amphiphilic molecule or macro-molecule; or a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity upon a chemical, photochemical, or biological reaction. Another aspect of the invention relates to multicationic compounds that are composed of three or more amino acids. The present invention also relates to the use of the pharmaceutical composition for delivery of nucleic acids to a cell. Moreover, the invention encompasses the non-viral vector compositions tethered to a surface. The surface-tethered compositions are useful for the delivery of nucleic acids to cells in contact with the surface. An additional embodiment of the invention relates to a hydrogel comprising a composition of the invention, and methods of using same for the delivery of genetic material to a cell.